Compare NCZ & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCZ | ALLO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.6M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | NCZ | ALLO |
|---|---|---|
| Price | $14.26 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 533.0K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $0.86 |
| 52 Week High | $3.15 | $3.78 |
| Indicator | NCZ | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 72.20 |
| Support Level | $13.75 | $1.30 |
| Resistance Level | $14.34 | $1.54 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 91.30 | 82.05 |
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.